Biomarin prepares for European approval of Ascendis competitor

US firm Biomarin has upgraded its financial expectations based on Q2, and is preparing a new drug that will challenge the existing market.

The EMA HQ in Amsterdam. | Photo: Rob Acket/EMA

US biotech firm Biomarin ended the second quarter with a revenue growth of 17 percent compared to the same period last year. The result was USD 501.7m.

Revenue for the first half year totaled USD 987.7m, a 6 percent increase compared to the first half of 2020.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs